Parkinson's syndrome and Parkinson's disease in mitochondrial disorders

Movement Disorders

Volumn 26, Issue 5, 2011, Pages 784-791

  Finsterer, Josef ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Extrapyramidal disease; Genetics; Metabolic disease; Mitochondrial DNA; Mitochondrial myopathy; Neurodegenerative disorder

Indexed keywords

ALPHA SYNUCLEIN; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LACTIC ACID; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MITOCHONDRIAL DNA; ROPINIROLE; TOLCAPONE;

BIOCHEMISTRY; CEREBROSPINAL FLUID; CLINICAL FEATURE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSKINESIA; GENE MUTATION; HUMAN; MUTATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE;

DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIAL DISEASES; MUTATION; PARKINSON DISEASE; PARKINSONIAN DISORDERS;

EID: 79955078128     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23651     Document Type: Review

References (77)

1. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol 2010; 9: 829-840.
2. Finsterer J. Central nervous system imaging in mitochondrial disorders. Can J Neurol Sci 2009; 36: 143-153.
3. De Coo IF, Renier WO, Ruitenbeek W, et al. A 4-base pair deletion in the mitochondrial cytochrome b gene associated with parkinsonism/MELAS overlap syndrome. Ann Neurol 1999; 45: 130-133.
4. Finsterer J, Jarius C, Baumgartner M. Parkinson's disease associated with impaired oxidative phosphorylation. Neuroradiology 2001; 43: 997-1000.
5. Horvath R, Kley RA, Lochmüller H, Vorgerd M. Parkinson syndrome, neuropathy, and myopathy caused by the mutation A8344G (MERRF) in tRNALys. Neurology 2007; 68: 56-58.
6. Finsterer J. Parkinson syndrome as a manifestation of mitochondriopathy. Acta Neurol Scand 2002; 105: 384-389.
7. Mancuso M, Nesti C, Petrozzi L, et al. The mtDNA A8344G "MERRF" mutation is not a common cause of sporadic Parkinson disease in Italian population. Parkinsonism Relat Disord 2008; 14: 381-382.
8. Finsterer J, Stöllberger C, Feichtinger H. Noncompaction and endocarditis in suspected mitochondrial disorder. Int J Cardiol 2008; 123: e45-e47.
9. Milone M, Liewluck T, Wang J, Leavin JA, Wong L-J. A novel splice site mutation of the POLG gene in two unrelated adults with ophthalmoparesis and myopathy. Acta Myol 2010; 29: 235.
10. Garcia-Cazorla A, Duarte S, Serrano M, et al. Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 2008; 8: 273-278.
11. Hara K, Yamamoto M, Anegawa T, Sakuta R, Nakamura M. Mitochondrial encephalomyopathy associated with parkinsonism and a point mutation in the mitochondrial tRNA(Leu)(UUR)) gene. Rinsho Shinkeigaku 1994; 34: 361-365.
12. García-Cazorla A, Rabier D, Touati G, et al. Pyruvate carboxylase deficiency: metabolic characteristics and new neurological aspects. Ann Neurol 2006; 59: 121-127.
13. Macaya A, Munell F, Burke RE, De Vivo DC. Disorders of movement in Leigh syndrome. Neuropediatrics 1993; 24: 60-67.
14. van Erven PM, Renier WO, Gabreëls FJ, Thijssen HO, Ruitenbeek W, Horstink MW. Hypokinesia and rigidity as clinical manifestations of mitochondrial encephalomyopathy: report of three cases. Dev Med Child Neurol 1989; 31: 81-91.
15. Davidzon G, Greene P, Mancuso M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 2006; 59: 859-862.
16. Egensperger R, Kösel S, Schnopp NM, Mehraein P, Graeber MB. Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. Neuropathol Appl Neurobiol 1997; 23: 315-321.
17. Kösel S, Grasbon-Frodl EM, Hagenah JM, Graeber MB, Vieregge P. Parkinson disease: analysis of mitochondrial DNA in monozygotic twins. Neurogenetics 2000; 2: 227-230.
18. Cavelier L, Erikson I, Tammi M, et al. MtDNA mutations in maternally inherited diabetes: presence of the 3397 ND1 mutation previously associated with Alzheimer's and Parkinson's disease. Hereditas 2001; 135: 65-70.
19. Siciliano G, Mancuso M, Ceravolo R, Lombardi V, Iudice A, Bonuccelli U. Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. J Neurol Neurosurg Psychiatry 2001; 71: 685-687.
20. Luoma PT, Eerola J, Ahola S, et al. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 2007; 69: 1152-1159.
21. Eerola J, Luoma PT, Peuralinna T, et al. POLG1 polyglutamine tract variants associated with Parkinson's disease. Neurosci Lett 2010; 477: 1-5.
22. Yamamoto M, Ujike H, Wada K, Tsuji T. Cerebrospinal fluid lactate and pyruvate concentrations in patients with Parkinson's disease and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). J Neurol Neurosurg Psychiatry 1997; 62: 290.
23. Gdynia HJ, Sperfeld AD, Unrath A, et al. Histopathological analysis of skeletal muscle in patients with Parkinson's disease and 'dropped head'/'bent spine' syndrome. Parkinsonism Relat Disord 2009; 15: 633-639.
24. Schapira AH. Evidence for mitochondrial dysfunction in Parkinson's disease-a critical appraisal. Mov Disord 1994; 9: 125-138.
25. Tanaka M, Kovalenko SA, Gong JS, et al. Accumulation of deletions and point mutations in mitochondrial genome in degenerative diseases. Ann N Y Acad Sci 1996; 786: 102-111.
26. Kösel S, Grasbon-Frodl EM, Mautsch U, et al. Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease. Neurogenetics 1998; 1: 197-204.
27. Grasbon-Frodl EM, Kösel S, Sprinzl M, von Eitzen U, Mehraein P, Graeber MB. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. Neurogenetics 1999; 2: 121-127.
28. Schnopp NM, Kösel S, Egensperger R, Graeber MB. Regional heterogeneity of mtDNA heteroplasmy in parkinsonian brain. Clin Neuropathol 1996; 15: 348-352.
29. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-517.
30. Reeve AK, Krishnan KJ, Elson JL, et al. Nature of mitochondrial DNA deletions in substantia nigra neurons. Am J Hum Genet 2008; 82: 228-235.
31. Keeney PM, Dunham LD, Quigley CK, Morton SL, Bergquist KE, Bennett JPJr. Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships. Exp Neurol 2009; 220: 374-382.
32. Borland MK, Mohanakumar KP, Rubinstein JD, et al. Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim Biophys Acta 2009; 1792: 68-74.
33. Simon DK, Pankratz N, Kissell DK, et al; Parkinson Study Group-PROGENI Investigators. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet 2010; 11: 53.
34. Vives-Bauza C, Andreu AL, Manfredi G, et al. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochem Biophys Res Commun 2002; 290: 1593-1601.
35. Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta 2010; 1802: 29-44.
36. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010; 31: 763-780.
37. Lin TK, Liou CW, Chen SD, et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease. Chang Gung Med J 2009; 32: 589-599.
38. Grünewald A, Gegg ME, Taanman JW, et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol 2009; 219: 266-273.
39. Rakovic A, Grünewald A, Seibler P, et al. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 2010; 19: 3124-3137.
40. Chu CT. A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. Hum Mol Genet 2010; 19: R28-R37.
41. Matsuda N, Sato S, Shiba K, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 2010; 189: 211-221.
42. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010; 8: e1000298.
43. Tan EK. PINK1 mutations and differential effects on mitochondrial function. Exp Neurol 2010; 221: 10-12.
44. Gispert S, Ricciardi F, Kurz A, et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009; 4: e5777.
45. Liu W, Vives-Bauza C, Acín-Peréz- R, et al. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One 2009; 4: e4597.
46. Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ. Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc Natl Acad Sci U S A 2010; 107: 11835-11840.
47. Okatsu K, Saisho K, Shimanuki M, et al. p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes Cells 2010; 15: 887-900.
48. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 2010; 107: 378-383.
49. Ziviani E, Whitworth AJ. How could Parkin-mediated ubiquitination of mitofusin promote mitophagy? Autophagy 2010; 6 [Epub ahead of print].
50. Foti R, Zucchelli S, Biagioli M, et al. Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. J Biol Chem 2010; 285: 18565-18574.
51. Irrcher I, Aleyasin H, Seifert EL, et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 2010; 19: 3734-3746.
52. Thomas B. Parkinson's disease: from molecular pathways in disease to therapeutic approaches. Antioxid Redox Signal 2009; 11: 2077-2082.
53. Bayir H, Kapralov AA, Jiang J, et al. Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J Biol Chem 2009: 284: 15951-15969.
54. McFarland MA, Ellis CE, Markey SP, Nussbaum RL. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics 2008; 7: 2123-2137.
55. Iaccarino C, Crosio C, Vitale C, Sanna G, Carrì MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007; 16: 1319-1326.
56. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci 1985; 36: 2503-2508.
57. Mizuno Y, Saitoh T, Sone N. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 1987; 143: 971-976.
58. de Moura MB, dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 2010; 51: 391-405.
59. Snow BJ, Rolfe FL, Lockhart MM, et al; Protect Study Group. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 2010; 25: 1670-1674.
60. Bisaglia M, Soriano ME, Arduini I, Mammi S, Bubacco L. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim Biophys Acta 2010; 1802: 699-706.
61. Pienaar IS, Dexter DT, Burkhard PR. Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis. Expert Rev Proteomics 2010; 7: 205-226.
62. Trimmer PA, Bennett JP Jr. The cybrid model of sporadic Parkinson's disease. Exp Neurol 2009; 218: 320-325.
63. Misiak M, Beyer C, Arnold S. Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons. Biochim Biophys Acta 2010; 1797: 1178-1188.
64. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 2008; 1147: 93-104.
65. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993; 34: 715-723.
66. Wilcox RA, Churchyard A, Dahl HH, Hutchison WM, Kirby DM, Thyagarajan D. Levodopa response in Parkinsonism with multiple mitochondrial DNA deletions. Mov Disord 2007; 22: 1020-1023.
67. Huang JY, Chuang JI. Fibroblast growth factor 9 upregulates heme oxygenase-1 and gamma-glutamylcysteine synthetase expression to protect neurons from 1-methyl-4-phenylpyridinium toxicity. Free Radic Biol Med 2010; 49: 1099-1108.
68. Thobois S, Vighetto A, Grochowicki M, Godinot C, Broussolle E, Aimard G. Leber "plus" disease: optic neuropathy, parkinsonian syndrome and supranuclear ophthalmoplegia. Rev Neurol (Paris) 1997; 153: 595-598.
69. Dermaut B, Seneca S, Dom L, et al. Progressive myoclonic epilepsy as an adult-onset manifestation of Leigh syndrome due to m.14487T>C. J Neurol Neurosurg Psychiatry 2010; 81: 90-93.
70. Chalmers RM, Brockington M, Howard RS, Lecky BR, Morgan-Hughes JA, Harding AE. Mitochondrial encephalopathy with multiple mitochondrial DNA deletions: a report of two families and two sporadic cases with unusual clinical and neuropathological features. J Neurol Sci 1996; 143: 41-45.
71. Baloh RH, Salavaggione E, Milbrandt J, Pestronk A. Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle. Arch Neurol 2007; 64: 998-1000.
72. Hudson G, Schaefer AM, Taylor RW, et al. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 2007; 64: 553-557.
73. Remes AM, Hinttala R, Kärppä M, et al. Parkinsonism associated with the homozygous W748S mutation in the POLG1 gene. Parkinsonism Relat Disord 2008; 14: 652-654.
74. Invernizzi F, Varanese S, Thomas A, Carrara F, Onofrj M, Zeviani M. Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism. Neuromuscul Disord 2008; 18: 460-464.
75. Galassi G, Lamantea E, Invernizzi F, et al. Additive effects of POLG1 and ANT1 mutations in a complex encephalomyopathy. Neuromuscul Disord 2008; 18: 465-470.
76. Vandenberghe W, Van Laere K, Debruyne F, Van Broeckhoven C, Van Goethem G. Neurodegenerative Parkinsonism and progressive external ophthalmoplegia with a Twinkle mutation. Mov Disord 2009; 24: 308-309.
77. Betts-Henderson J, Jaros E, Krishnan KJ, et al. Alpha-synuclein pathology and Parkinsonism associated with POLG1 mutations and multiple mitochondrial DNA deletions. Neuropathol Appl Neurobiol 2009; 35: 120-124.